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Abstract: Background and aims: Peripheral arterial disease (PAD) is an important cause of morbidity
and mortality with little effective medical treatment currently available. Nitric oxide (NO) is crucially
involved in organ perfusion, tissue protection and angiogenesis. Methods: We hypothesized that a novel
NO-donor, MPC-1011, might elicit vasodilation, angiogenesis and arteriogenesis and in turn improve limb
perfusion, in a hindlimb ischemia model. Hindlimb ischemia was induced by femoral artery ligation in
Sprague-Dawley rats, which were randomized to receive either placebo, MPC-1011, cilostazol or both,
up to 28 days. Limb blood flow was assessed by laser Doppler imaging. Results: After femoral artery
occlusion, limb perfusion in rats receiving MPC-1011 alone or in combination with cilostazol was increased
throughout the treatment regimen. Capillary density and the number of arterioles was increased only
with MPC-1011. MPC-1011 improved vascular remodeling by increasing luminal diameter in the ischemic
limb. Moreover, MPC-1011 stimulated the release of proangiogenic cytokines, including VEGF, SDF1฀
and increased tissue cGMP levels, reduced platelet activation and aggregation, potentiated proliferation
and migration of endothelial cells which was blunted in the presence of soluble guanylyl cyclase inhibitor
LY83583. In MPC-1011-treated rats, Lin-/CD31+/CXCR4+ cells were increased by 92.0% and Lin-
/VEGFR2+/CXCR4+ cells by 76.8% as compared to placebo. Conclusions: Here we show that the NO
donor, MPC-1011, is a specific promoter of angiogenesis and arteriogenesis in a hindlimb ischemia model
in an NO-cGMP-VEGF- dependent manner. This sets the basis to evaluate and confirm the efficacy of
such therapy in a clinical setting in patients with PAD and impaired limb perfusion.
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H I G H L I G H T S
• PAD is a debilitating disease caused by abnormal narrowing of arteries with little or no medical treatment options existing.
• Novel and unique NO donor, MPC-1011, promotes angiogenesis via NO-mediated signaling and proliferation of endothelial cells.
• Thus, MPC-1011 might be successfully used in clinical setting in patients with PAD or in those with impaired limb perfusion.
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A B S T R A C T
Background and aims: Peripheral arterial disease (PAD) is an important cause of morbidity and mortality with
little effective medical treatment currently available. Nitric oxide (NO) is crucially involved in organ perfusion,
tissue protection and angiogenesis.
Methods: We hypothesized that a novel NO-donor, MPC-1011, might elicit vasodilation, angiogenesis and ar-
teriogenesis and in turn improve limb perfusion, in a hindlimb ischemia model. Hindlimb ischemia was induced
by femoral artery ligation in Sprague-Dawley rats, which were randomized to receive either placebo, MPC-1011,
cilostazol or both, up to 28 days. Limb blood flow was assessed by laser Doppler imaging.
Results: After femoral artery occlusion, limb perfusion in rats receiving MPC-1011 alone or in combination with ci-
lostazol was increased throughout the treatment regimen. Capillary density and the number of arterioles was increased
only with MPC-1011. MPC-1011 improved vascular remodeling by increasing luminal diameter in the ischemic limb.
Moreover, MPC-1011 stimulated the release of proangiogenic cytokines, including VEGF, SDF1α and increased tissue
cGMP levels, reduced platelet activation and aggregation, potentiated proliferation and migration of endothelial cells
which was blunted in the presence of soluble guanylyl cyclase inhibitor LY83583. In MPC-1011-treated rats, Lin−/
CD31+/CXCR4+ cells were increased by 92.0% and Lin−/VEGFR2+/CXCR4+ cells by 76.8% as compared to placebo.
Conclusions: Here we show that the NO donor, MPC-1011, is a specific promoter of angiogenesis and arter-
iogenesis in a hindlimb ischemia model in an NO-cGMP-VEGF- dependent manner. This sets the basis to evaluate
and confirm the efficacy of such therapy in a clinical setting in patients with PAD and impaired limb perfusion.
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1. Introduction
Although coronary artery disease and stroke are the leading causes
of death worldwide [1,2], many people also suffer from peripheral ar-
terial disease (PAD) characterized by impaired blood flow to the lower
extremities, claudication pain and severe exercise intolerance [3]. The
most common cause of peripheral artery disease is atherosclerosis,
however, less common causes include inflammatory disorders of the
arterial wall, vasculitis, and noninflammatory arteriopathies [4]. Of
note, most studies using revascularization strategies [5–7] or pharma-
cological treatments [8,9] indicate that patients with PAD have a
markedly increased risk for death as well as cardiovascular events in-
cluding critical limb ischemia with potentially life-changing limb loss.
Occlusive atherosclerosis occurs as a last step of endothelial nitric
oxide (NO) deficiency, hence limiting signal transduction necessary for
normal vascular function [10]. NO is ubiquitous molecule able to dif-
fuse across cell membranes, modulating many physiological responses
including gene expression, apoptosis, platelet function, vascular smooth
muscle cell relaxation and proliferation, neurotransmission, memory,
and immune stimulation [11–15]. Thus, delivery of NO appears to be an
attractive therapeutic option in several cardiovascular conditions, in-
cluding PAD, and this delivery is achieved through NO-releasing drugs.
Those are pharmacologically active compounds that release NO in vitro
and in vivo, e.g. sodium nitroprusside [16], organic nitrates and nitrite
esters [17] and S- nitrosothiols [18]. Such NO-releasing drug is MPC-
1011 (mirandaPharmaceuticalsR Ltd., Basel, Switzerland), an organic
nitrate with NO-releasing properties. Unlikely to other organic nitrates,
MPC-1011 does not induce either in vitro tolerance, in vivo cross toler-
ance, or oxidative stress in vitro and in vivo [19,20]. Thus, chronic ad-
ministration of such ‘super nitrate’ is conceptually very tempting as it is
likely that MPC-1011 will improve perfusion of muscle tissue and hence
clinical outcome in PAD patients. In order to test this hypothesis, the
currently approved drug for PAD, phosphodiesterase III inhibitor ci-
lostazol (Pletal®, 6-[4-(1-cyclo-hexyl-1H-tetrazol-5-yl) butoxy]-3,4-di-
hydro-2(1H)- quinolinone) was administered alone or combined with
MPC-1011 in an animal model of PAD.
2. Materials and methods
A detailed description of the methods used in this study can be
found in Supplementary Materials.
2.1. Animals
Four-week-old male Sprague-Dawley (SD) rats were used for all the
experiments. The animals were kept in the Core Rodent Facility at the
Department of Physiology, University of Zurich, Switzerland. The food
regimen and treatment assignments are explained in detail in
Supplementary Materials.
2.2. Surgical procedure of hind-limb ischemia
During surgery, animals were positioned on a heating plate to keep
the body temperature constant. Aseptic surgery was performed by a
linear incision in the right groin down to the knee. Unilateral hindlimb
ischemia will be surgically induced by left femoral artery occlusion as
previously described [21]. Detail description of the surgical procedure
can be found in the upplementary Materials.
2.3. Surgical procedure and osmotic minipump implantation
Those rats that were randomly assigned to receive either MPC-1011
alone, or in combination with cilostazol, were implanted s.c. with
miniosmotic pumps for continuous MPC-1011 delivery (Model 2004,
Alzet, Cupertino, CA, USA; length 3 cm, diameter: 0.7 cm, weight: 1.1 g,
total displaced volume: 1 ml). Detailed description of the miniosmotic
pump implantation can be found in Supplementary Materials.
2.4. Drugs and dosages
After hind limb ischemia ligation, the rats were randomly assigned
to receive either MPC-1011 using miniosmotic pump (3.6 mg/day
subcutaneously into the back of the animals at the same time when hind
limb ligation was induced), cilostazol (100 mg/kg/bi-daily), MPC-1011
plus cilostazol, or placebo. MPC-1011 was kindly provided by
mirandaPharmaceuticals, Basel, Switzerland.
2.5. Laser Doppler imaging
For laser Doppler imaging, the rats were anesthetized using iso-
fluorane (5% induction, 1–3% for the maintenance), placed in the
prone position on a circulating warm water blanket (37 °C), and posi-
tioned under the laser Doppler imager (Moor Instruments, Axminster,
UK). Details on laser Doppler imaging procedure and the quantification
are described in the Supplementary Materials.
2.6. MicroCT imaging
Directly after the operation and induction of hindlimb ischemia, the
animals were transferred into the microCT apparatus (Quantum Fx
microCT Imaging System, PerkinElmer, Waltham MA) where the ima-
ging took place. Preparation of the animals for CT imaging and the
procedure details can be found in the Supplementary Materials.
2.7. Post mortem analysis
At the end of the experiment (i.e. 28, 14, or 6 days) animals were
anesthetized using CO2 and euthanized by exsanguination and the ad-
ductor muscles were isolated and used for immunohistochemistry.
Hematoxylin and eosin staining was used for histological examination
as described in the Supplementary Materials.
Slides were scanned using digital slide scanner NanoZoomer-
XRC12000 (Hamamatsu, Japan) and angiogenic responses were mea-
sured by the analysis of capillary density and the ratio of the number of
capillaries per muscle fiber. The total number of muscle fibers and ca-
pillaries present in 20 fields (40x magnification) per slide was counted
and the capillary densities were expressed by numbers of capillaries/
mm2. Arterioles density was quantified in histological sections of the
adductor muscle. Results were expressed as number of arterioles/mm2
of tissue. To check the arteriolar remodeling response to the ischemia,
the immunohistochemistry was performed as described above. The
measurements of wall and luminal areas and diameter calculation of
arterioles were performed in an equal random area for each histological
sample. Evaluation of arteriole remodeling was based on the classifi-
cation described earlier [21].
2.8. Platelet activation assay
After 2 weeks of treatment with MPC-1011, cilostazol, MPC-1011
plus cilostazol or placebo, respectively rat platelets were isolated from
1 ml blood anticoagulated with sodium citrate (9:1) and processed as
explained in the Online Supplement, Detailed Methods. Acquisition was
done on a FACSCanto (BD Biosciences) and mean fluorescence in-
tensities for 10′000 events recorded and calculated with the FACSDiva
software (BD Biosciences).
2.9. VEGF, SDF1α and cGMP levels
Levels of vascular endothelial growth factor (VEGF), SDF1α and
cyclic guanosine monophosphate (cGMP) were quantified in homo-
genates of the tibialis muscle in treated animals 6 days after the op-
eration, and analyzed as described in the Supplementary Materials.
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2.10. FACS analysis of proangiogenic endothelial progenitor cells
Mobilization of putative stem cells from bone marrow into the
peripheral blood in the placebo and treated groups of the rats was as-
sessed by flow cytometry in whole blood, 6 days after surgery, as de-
scribed in the Supplementary Materials.
2.11. Endothelial cells scratch assay
Human aortic endothelial cells (HAECs) migration was assessed
using the scratch assay in the presence of MPC-1011 and cGMP in-
hibitor (Ly 83583, Sigma-Aldrich Chemie GmbH, Buchs, Switzerland)
as explained in the Supplementary Materials.
2.12. Endothelial cells transmigration assay
HAECs, the passage number 7, were cultivated with EGM-2 10% for
transmigration assay and were analyzed as described in the
Supplementary Materials.
2.13. Statistical analysis
All results are expressed as the mean ± SEM. Comparisons be-
tween two groups were performed using Student's t-test or by one-way
ANOVA with Bonferroni correction for multiple group comparisons.
Blood flow recovery data were analyzed using two-way ANOVA, fol-
lowed by Bonferroni post-hoc analysis. A p-value smaller than 0.05 was
considered statistically significant. GraphPad Prism (version 8.4.2,
GraphPad Software, San Diego, CA, USA, www.graphpad.com) was
used for the statistical analysis.
3. Results
3.1. Blood perfusion in experimental hindlimb ischemia
Laser Doppler imaging was used to assess blood perfusion after in-
duction of hind limb ischemia and randomization of the animals to
receive either MPC-1011 alone, cilostazol alone, MPC-1011 plus cilos-
tazol or placebo, respectively (Fig. 1). Successful anatomical removal of
the vessels was verified by microCT technology (Supplementary Video).
Induction of unilateral hind limb ischemia was associated with a sig-
nificant reduction of blood flow after 6, 9 and 15 days, as assessed by
laser Doppler imaging.
Supplementary video related to this article can be found at https://
doi.org/10.1016/j.atherosclerosis.2020.05.012
Of interest, laser Doppler imaging documented increased blood
perfusion in rats receiving MPC-1011 (10.5%, 8.4%, and 16.4% versus
placebo, respectively; p < 0.05) or the combination of MPC-1011 plus
cilostazol (15.8%, 12.4%, 16.4% versus placebo, respectively;
p < 0.05), while blood flow in those receiving cilostazol only did not
differ from placebo-treated animals (Fig. 2A).
Similarly, the area under the curve (AUC) was increased in MPC-
1011- or combination-treated rats (by 44.2% and 49.7%, respectively;
p < 0.05; MPC-1011 vs. placebo and MPC- 1011 versus cilostazol,
respectively; by 54.2% and 60.1%; p < 0.05, combination vs. placebo
and combination vs. cilostazol, respectively; Fig. 2B).
3.2. Pro-angiogenic effects of MPC-1011
After 2 weeks of treatment, capillary number was increased in rats
receiving MPC-1011 and in combination-treated groups as compared to
placebo or cilostazol (20.4% and 33.8%, p < 0.05 MPC-1011 vs.
Fig. 1. Representative image of blood perfusion
upon hindlimb ischemia.
Representative image of blood perfusion in rats
treated with placebo, cilostazol, MPC-1011, and
cilostazol plus MPC-1011 before the surgery,
immediately after the surgery (day 0) and 15
days after the surgery in a color-coded re-
presentation where the right hindlimb was li-
gated (blue color) and left hindlimb was not
operated (red color) and latter serves as an in-
ternal standard for blood perfusion determina-
tion.
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placebo and MPC-1011 vs. cilostazol, respectively; 32.6% and 47.4%,
p < 0.01, combination treatment vs. placebo and combination treat-
ment vs. cilostazol, respectively) (Fig. 3A and Supplementary Fig. 1A).
Similarly, after 4 weeks, the number of capillaries was increased in
MPC-1011- and combination-treated groups as compared to those re-
ceiving placebo or cilostazol alone (24.6% and 28.7%, p < 0.01; MPC-
1011 versus placebo and MPC-1011 versus cilostazol, respectively;
25.5% and 29.6%, p < 0.01; combination versus placebo and combi-
nation versus cilostazol, respectively; Fig. 3B).
The effect of MPC-1011 and combination therapy was highly spe-
cific and only affected the operated hind limb, while no changes in
capillary number were detected in the contralateral (non-operated)
limbs (Supplementary Fig. 1B-D).
3.3. Pro-arteriogenic effects of MPC-1011
After 4 weeks, the number of arterioles was increased in MPC-1011-
and combination-treated groups as compared to placebo or cilostazol
alone (54.5% and 42.3%, respectively, p < 0.05, MPC-1011 vs. pla-
cebo and MPC-1011 vs. cilostazol, respectively; 46.1% and 34.6%,
p < 0.05, combination vs. placebo and combination vs. cilostazol, re-
spectively), while no change was observed in contralateral, non-oper-
ated limb (Fig. 3C; Supplementary Fig. 2A and B).
3.4. MPC-1011 and vascular remodeling
After 6 days of treatment, diameter of the arterioles was increased in
MPC-1011- and combination-treated groups as compared to placebo or
cilostazol alone (21.1% and 17.6%, p < 0.05, MPC-1011 vs. placebo
and MPC-1011 vs. cilostazol, respectively; 28.2% and 24.5%, p < 0.01
and p < 0.05, combination vs. placebo and combination vs. cilostazol,
respectively; Supplementary Fig. 3A). At 6 days, the wall area size was
not affected by any of the treatments (Supplementary Fig. 3B), and the
ratio of arterial wall area and luminal area was reduced in MPC-1011
and combination-treated as compared to cilostazol (22.8%, p < 0.05,
MPC-1011 vs. cilostazol and 19.3%, p < 0.05, combination vs.
Fig. 2. Blood perfusion in four treatment arms of rats that underwent hindlimb ischemia.
Blood perfusion in ligated hindlimb expressed as % blood flow compared to contralateral limb (A) and area under the curve in four treatment arms (B). Blood flow
was measured immediately before and after surgery using laser Doppler imaging and was measured every third day for a total duration of 3 weeks. Data are presented
as mean ± SEM. *p < 0.05. Bonferroni-adjusted p values are shown. N = 9–11, where N represents an individual animal.
Fig. 3. Capillary and arteriole density in four different treatment groups upon hindlimb ischemia.
Capillary density, expressed as number of capillaries per mm2, in ligated limb after 2 (A) and 4 (B) weeks of treatment; (C) arterioles density in ischemic limbs from
four experimental groups. Arterioles density was expressed as number of arterioles per mm2 in ligated limb after 4 weeks of treatment. The total number of muscle
fibers and capillaries present in 20 fields (40x magnification) per slide was counted and the capillary densities were expressed by numbers of capillaries/mm2-. Data
are presented as mean ± SEM. *p < 0.05 and **p < 0.01. Bonferroni-adjusted p values are shown. N = 4–5, where N represents an individual animal.
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Fig. 4. Proangiogenic response in vivo and in vitro.
cGMP- (A), VEGF- (B) and SDF1α-levels (C) in homogenates of tibialis muscle from rats treated for 6 days with either placebo, MPC-1011 alone, cilostazol alone, or
MPC- 1011 plus cilostazol; (D) in vitro effects of MPC-1011 in the presence or absence of cGC inhibitor, LY83583, on gap closure; population of Lin− /VEGFR2+/
CXCR4+ (E) and Lin−/CD31+/CXCR4+ (F) cells from whole rat blood in four treatment arms. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01 and
***p < 0.001. Bonferroni-adjusted p values are shown. N = 7–9 where N represents an individual animal. For cell culture experiments, N = 3–4 where N represents
a biological replicate.
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cilostazol, respectively; Supplementary Fig. 3C).
Similar effects were observed at 2 weeks: diameter of the arterioles
was increased in MPC-1011- and combination-treated groups as com-
pared to placebo or cilostazol alone (21.0% and 14.2%, p < 0.05,
MPC-1011 vs. placebo and MPC-1011 vs. cilostazol, respectively; 26.6%
and 19.6%, p < 0.01 and p < 0.05, combination vs. placebo and
combination vs. cilostazol, respectively) (Supplementary Fig. 4A), while
the wall area remained unaffected in all groups (Supplementary
Fig. 4B). Accordingly, the ratio of arterial wall area and luminal area
was reduced with MPC-1011 and combination-treated also at that time
point as compared to placebo or cilostazol alone (23.6% and 38.0%,
p < 0.05 and p < 0.001, MPC- 1011 vs. placebo and MPC-1011 vs.
cilostazol, respectively; 19.2% and 34.6%, p < 0.05 and p < 0.01,
combination vs. placebo and combination vs. cilostazol, respectively);
Supplementary Fig. 4C).
After 4 weeks, measured diameter of the arterioles was increased
with MPC-1011 and combination-treated as compared to placebo or
cilostazol alone (23.1% and 27.0%, p < 0.05, MPC-1011 vs. placebo
and MPC-1011 vs. cilostazol, respectively; 25.0% and 28.8%, p < 0.05,
combination vs. placebo and combination vs. cilostazol, respectively;
Supplementary Fig. 5A). The wall area size in all groups remained
unaffected (Supplementary Fig. 5B), but the ratio of arterial wall area
and luminal area was reduced with MPC-1011 and combination-treated
as compared to placebo or cilostazol alone (23.9% and 34.1%,
p < 0.01 and p < 0.001, MPC-1011 vs. placebo and MPC-1011 vs.
cilostazol, respectively; 22.0% and 32.3%, p < 0.01 and p < 0.001,
combination vs. placebo and combination vs. cilostazol, respectively;
Supplementary Fig. 5C).
The effects of remodeling by MPC-1011- and combination-treatment
were highly specific as no changes in the wall/luminal area or arteriolar
diameter were noted in the contralateral non-ischemic limbs
(Supplementary Fig. 6).
3.5. MPC-1011 increases cGMP, VEGF and SDF1α levels and stimulates
CXCR4+/VEGFR2+ proangiogenic EPCs
After 6 days, MPC-1011 increased tissue cGMP levels in homo-
genates of tibialis muscle by 60.2% compared to placebo (Fig. 4A).
Muscle VEGF levels were increased by MPC-1011 by 42.2% (Fig. 4B),
while SDF1α levels were increased by 30.7% as compared to placebo
(Fig. 4C).
When HAECs were incubated with the sGC inhibitor LY83583, the
capacity gap closure decreased by 72.9% as compared to vehicle
(p < 0.001), while MPC-1011 alone increased gap closure by 19.6% as
compared to vehicle-treated cells. In cells pre-incubated with LY83583,
MPC-1011 led to a 3.4-fold increase in gap closure as compared to the
inhibitor alone (p < 0.001; Fig. 4D).
FACS analysis indicated in serum of MPC-1011-treated rats a 76.8%
increase of Lin−/VEGFR2+/CXCR4+ cell population vs. placebo
(Fig. 4E), while Lin−/CD31+/CXCR4+ cells population was increased
for a 92.0% vs. placebo (Fig. 4F).
3.6. Endothelial cell transmigration assay
Migration of endothelial cells in modified Boyden chambers against
full medium as a chemoattractant was increased by MPC-1011 by
19.0% (p < 0.01, vs. vehicle), while transmigration was reduced by -
-31.7% in the presence of the soluble guanylate cyclase inhibitor,
LY83583 (10−5 M; p < 0.001 vs. MPC-1011-stimulated migration)
(Fig. 5A). If MPC-1011 was used as a chemoattractant, migration of
endothelial cells increased by 92.0% (p < 0.001, vs. vehicle), while
LY83583 reduced transmigration against MPC-1011 by 18.0%
(p < 0.01 vs. MPC-1011 alone; Fig. 5B).
3.7. MPC-1011 prevents platelet aggregation
Flow cytometry of the surface marker P-selectin in platelets in a
resting, unstimulated state, indicated that in MPC-1011-treated rats its
expression level was reduced by 44.0% as compared to placebo-treated
rats (Supplementary Fig. 7; p < 0.05).
4. Discussion
To the best of our knowledge, we here for the first time show im-
portant effects of the NO donor MPC-1011 on blood flow, angiogenesis,
arteriogenesis, tissue remodeling in a rat model of PAD in vivo sup-
ported by in vitro studies on cell proliferation and transmigration.
Indeed, after femoral artery ligation MPC-1011 increased blood flow,
Fig. 5. Transmigration assay of HAECs.
Transmigration of HAECs pretreated with MPC-1011 alone, MPC-1011 plus LY83583, and LY83583 alone against full medium as a chemoattractant (A), and
transmigration of untreated HAECs when VEGF alone, MPC-1011 alone or MPC-1011 plus LY83583 was used as chemoattractants (B). Data are presented as
mean ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001. Bonferroni-adjusted p values are shown. N = 4–8 where N represents a biological replicate.
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the number of capillaries as well as arterioles, induced positive vascular
remodeling, and increased tissue levels of VEGF, cGMP, and SDF1α. At
the cellular level MPC-1011 facilitated transmigration of endothelial
cells, a crucial component of the angiogenic process. Finally, MPC-1011
reduced the expression of P-selectin in platelets as well as platelet ag-
gregation.
NO is a central constituent of vascular homeostasis under physio-
logical conditions and particularly during tissue ischemia [22]. Hence,
NO substitution has become a promising pharmacological treatment for
cardiovascular conditions [23,24]. Although many structurally and
chemically diverse NO-donor compounds have been synthesized and
used widely in experimental studies, no NO-donor has been approved
for use in the clinic, mostly due to development of nitrate tolerance
leading to loss of potency and induction of vascular oxidative stress.
MPC-1011 (2-nitrooxyethylammoniumnitrate, 2-aminoethyl nitrate
[AEN], itramin tosylate) belongs to the class of organic nitrates that
mediate relaxation by generation of NO or related species. It has been
marketed for the indication of angina pectoris between 1957 and 1969
under the trade name Nilatil ® (Pharmacia) [25] and was shown to have
favourable properties in vivo and in vitro [19,20], suggesting clinical
superiority over established compounds such as nitroglycerine/glyceryl
trinitrate (GTN) [26–29]. MPC-1011 has a potent vasodilatory proper-
ties ex vivo, it does not lead to oxidative stress in isolated heart mi-
tochondria [30], and unlikely to GTN, biotransformation of MPC-1011
is not mediated by mitochondrial aldehyde dehydrogenase (ALDH-2)
[19].
To test the hypothesis that use of the NO donor MPC-1011 would be
better than currently existing PAD treatment options such as cilostazol,
we used a rat model of an induced hindlimb ischemia. Since PAD has
traditionally been identified as a male-dominant disease, we used male
rats for inducing hindlimb ischemia. It is worth mentioning that some
population trends and studies [31,32] suggest that women are affected
at least as often as men, and thus, gender-based differences might not
play crucial role in presentation of PAD. We performed computer to-
mography imaging using ExiTron™ nano 12000 nanoparticles and
successfully demonstrated removal of the vessels in vivo. Further, using
laser Doppler imaging we demonstrated a marked and persistent in-
crease in blood perfusion over - 2 weeks testing period of MPC-1011
administration either alone or in combination with cilostazol, while no
increase in blood perfusion was achieved by cilostazol alone. The effect
of MPC-1011 in our rodent hindlimb ischemia model was a specific
angiogenic response to reduced limb perfusion, since the effects were
seen only in ischemic tissue and not in the contralateral, not operated
leg. Our data are in line with the improved revascularization in chronic
ischemia upon dietary nitrate supplementation [33] as well as with the
enhancement of ischemia-induced angiogenesis and arteriogenesis
upon chronic nitrite administration [34].
Significantly reduced NO bioavailability is the main factor to the
impaired endothelial function that leads to abnormal vascular re-
activity. Angiogenic potential of endothelial cells depends on bio-
synthesis and release of well-established angiogenic molecules, in-
cluding vascular cell adhesion molecule (VCAM), prostacyclin and
VEGF, among others. Circulating VCAM-1, a biomarker of endothelial
dysfunction, in patients with PAD is elevated due to its function in
mediating adhesion of immune cells to the vascular endothelium in the
process of endothelial dysfunction and inflammation [35]. Similarly,
prostacyclin biosynthesis and release by endothelial progenitor cells
(EPCs) is shown to be a crucial angiogenic phenomenon that con-
tributes to their regenerative function [36]. Yet another important an-
giogenetic growth factor that affects proliferation, migration, survival
and permeability of endothelial cells is VEGF [37]. It upregulates the
expression of endothelial NO synthase (eNOS) and stimulates the re-
lease of NO that plays a critical role in its angiogenic action [38]. Thus,
NO is the crucial downstream mediator of VEGF-induced endothelial
cell proliferation and migration [39]. In turn, NO activates soluble
guanylate cyclase (sGC), resulting in elevated cGMP levels that can
augment ischemia-induced angiogenesis. cGMP is a secondary mes-
senger which leads to vascular smooth muscle cells relaxation, vaso-
dilation and congruently increased blood flow. In line with this concept,
cGMP tissue levels were enhanced in MPC-1011 treated animals de-
monstrating that the NO-donor – as other organic nitrates - increases
cGMP levels at sites of ischemia [40]. Of note, in endothelial cells the
soluble guanylyl cyclase inhibitor LY83583, abolished VEGF-induced
angiogenesis as demonstrated by the gap-closure assay. The propensity
of the endothelial cells to migrate and seal the gap was markedly re-
duced by LY83583 in accordance with its known inhibitory effects on
VEGF-mediated angiogenic responses [41]. The migration and pro-
liferation of the endothelial cells upon exposure to MPC-1011 was also
examined in the Boyden chamber. Our data show unequivocally that
MPC-1011 improved cellular migration and proliferation in vitro. Fur-
ther, these processes must be at least partially mediated by cGMP, since
LY83583 again reduced the capacity of cells pre-incubated with MPC-
1011 to proliferate and migrate against the chemoattractant gradient.
These results are in line with already published observation on stimu-
latory effects of nitrites on endothelial proliferation and migration in an
NO/VEGF- dependent manner in vitro [42] and in vivo [34].
VEGF is also involved in the recruitment of bone marrow-derived
cells to ischemic tissue by stimulating release of stromal-derived factor
(SDF)-1α from platelets. SDF-1α promotes retention of bone marrow-
derived cells at damaged sites via its receptor, CXC chemokine receptor
type 4 (CXCR4) [43]. The mobilization of cells that express receptors
for VEGF and SDF-1α [44] to ischemic tissues is critical for angiogen-
esis. This was supported by our FACS analysis of whole blood sorted for
different cell surface receptors where we showed an increase of the
CXCR4+ and VEGFR2+ cell populations upon MPC-1011 treatment.
Thus, MPC-1011 not only stimulates VEGF release, but simultaneously
affects the release of SDF-1α which in turn acts on its cognate receptor
CXCR4 and mobilizes cells into the area of injury and promotes re-
vascularization of damaged tissues. A potential limitation of the effects
described here is the fact that certain solid tumors are able to grow and
metastatically spread due to an abnormal VEGF expression [45], an
effect that would be addressed during clinical development of MPC-
1011.
Finally, we observed a reduction in platelet activation in rats treated
with MPC-1011 as assessed by platelet P-selection expression in a non-
stimulated state. This corroborates evidence that NO donors inhibit
platelet aggregation in vitro and in vivo via the NO-cGMP pathway [46]
an effect that would also be therapeutically favourable in the PAD
population prone to atherothrombotic complications in the leg as well
as the heart and brain.
In conclusion, we demonstrate that chronic treatment with the nitric
oxide donor MPC- 1011 has a high potential for selectively restoring
perfusion to chronically ischemic peripheral tissues as it stimulates
various aspects of vascular remodeling such as angiogenesis and ar-
teriogenesis in a NO-dependent manner without tolerance.
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